HIGHLIGHTS
- who: Antoine Domenger and colleagues from the United States University of Turin, Italy have published the research work: Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma, in the Journal: (JOURNAL)
- what: The authors show in this study that both the toxicity of Myco and synergy with Bz operate in LenR and BzR LenR MM1S cells. The work suggests that blocking Sec61 is a promising therapeutic avenue for the treatment of refractory or relapsed MM.
SUMMARY
Multiple myeloma (MM) is a hematological malignancy of plasma cells . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.